The current stock price of CFMS is 2.26 USD. In the past month the price increased by 0.89%. In the past year, price decreased by -65.23%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.65 | 222.59B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.9 | 201.13B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.24 | 149.74B | ||
| SYK | STRYKER CORP | 28.27 | 142.38B | ||
| IDXX | IDEXX LABORATORIES INC | 57.81 | 58.21B | ||
| BDX | BECTON DICKINSON AND CO | 13.3 | 54.98B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.18 | 49.48B | ||
| RMD | RESMED INC | 25.09 | 36.26B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.26 | 36.10B | ||
| DXCM | DEXCOM INC | 34.15 | 24.77B | ||
| PODD | INSULET CORP | 68.02 | 21.87B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.71 | 18.78B |
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The firm offers knee replacement products and knee replacement products. The firm's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The firm owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Conformis Inc
600 Technology Drive
Billerica MASSACHUSETTS 01821 US
CEO: Mark A. Augusti
Employees: 295
Phone: 17813459001.0
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The firm offers knee replacement products and knee replacement products. The firm's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The firm owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
The current stock price of CFMS is 2.26 USD.
CFMS does not pay a dividend.
CFMS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CFMS.
Conformis Inc (CFMS) currently has 295 employees.
Conformis Inc (CFMS) has a market capitalization of 17.80M USD. This makes CFMS a Nano Cap stock.
ChartMill assigns a technical rating of 6 / 10 to CFMS. When comparing the yearly performance of all stocks, CFMS is one of the better performing stocks in the market, outperforming 89.18% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CFMS. Both the profitability and financial health of CFMS have multiple concerns.
Over the last trailing twelve months CFMS reported a non-GAAP Earnings per Share(EPS) of -5.61. The EPS increased by 34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.64 |
8 analysts have analysed CFMS and the average price target is 2.32 USD. This implies a price increase of 2.45% is expected in the next year compared to the current price of 2.26.
For the next year, analysts expect an EPS growth of 24.27% and a revenue growth -8.57% for CFMS